The World Health Organization (WH0) has recommended two drugs, baricitinib and sotrovimab, for treatment of Covid-19.
Baricitinib
Baricitinib, which is also used to treat rheumatoid arthritis, has been “strongly recommended” for patients with severe or critical Covid-19 in combination with corticosteroids.
It is part of a class of drugs called Janus kinase (JAK) inhibitors that suppress the overstimulation of the immune system.
It is an oral drug, and provides an alternative to other arthritis drugs called Interleukin-6 receptor blockers, recommended by WHO in July 2021.
Sotrovimab
Sotrovimab, developed by GlaxoSmithKline with US partner Vir Biotechnology Inc, is an investigational monoclonal antibody for use in treating conditions caused by coronavirus.
The WHO has conditionally recommended its use for treating mild or moderate Covid-19 in patients who are at high risk of hospitalisation.
These include patients who are older, are immunocompromised, and have underlying conditions like diabetes, hypertension and obesity, and are unvaccinated.
The US Food and Drug Administration (FDA) too has approved an emergency use authorization (EUA) for the therapy for the treatment of mild to moderate Covid-19 in patients above 12 years.
Dear Student,
You have still not entered your mailing address. Please enter the address where all the study materials will be sent to you. (If applicable).
